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Recent studies have demonstrated the existence of two chemically distinguishable 
classes of amyloid fibrils (1-5). One type of fibril is derived most often from amyloid 
fibrils associated with the primary form of the disease  and with multiple myeloma. 
It has  as  its maior component a  fragment of  an immunoglobulin light chain (5). 
The other type of amyloid fibril is generally seen in amyloid from one form of familial 
amyloidosis (familial Mediterranean fever) (FMF)  1 and secondary amyloidosis (2, 6). 
The recent delineation of the complete amino acid sequence of the major component 
of  this class  of amyloid fibril has shown it to have no homology with any known 
protein (1-4). This component has been termed A component by Hermodson et al. 
(2),  nonimmunoglobulin  acid soluble fraction (ASF) by us (1),  and amyloid of un- 
known origin (AUO) by Ein et al.  (3)  to distinguish it from the immunoglobulin- 
related types. 
ASF  consists of  76  amino acid  residues,  has  a  molecular weight  of  8,500 
daltons  and  a  heterogeneous  amino terminal  (1).  This  report  describes  im- 
munologic studies comparing ASF from different patients, and the prevalence 
and  partial  purification of  a  circulating component in human serum  which 
appears to be antigenically related to ASF. 
Methods 
Acid Soluble Fraction (ASF).--The preparations of ASF were the same as described earlier 
(1). They were obtained from tissues of patients with FMF, tuberculosis, Hodgkin's disease, 
and bronchiectasis. Since ASF was insoluble at physiologic pH, it was treated  with 0.1 N 
NaOH for 2 h and then neutralized with 0.1 N HCI. This degraded material  (DASF) was 
soluble in distilled water, physiologic saline, and other buffers. The DASF from a patient with 
FMF was labeled with 12~I using iodine monochloride (7).  ~ 
This work was supported by U. S. Public Health Service grants AM 02594, AM 01431, 
Michael and Helen Schaffer Fund and the New York Chapter of the Arthritis  Foundation, 
Inc., and National Institutes of Health Training grant 5 TO 5GM0 1668 from the National 
Institute of General Sciences. 
1  Abbreviations used in this paper: ASF, acid soluble fraction;  CFA, complete Freund's 
adjuvant; DASF, degraded ASF; FMF, familial Mediterranean fever. 
2 We would like to thank Dr. Marcus Rothschild for making this preparation for us. 
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Immunologic  Melhods.--Initially two rabbits were injected subcutaneously and in the foot- 
pads with a mixture of ASF dissolved in 0.02 N  HC1 and complete Freund's adjuvant (CFA) 
and two rabbits were injected with a  mixture of ASF dissolved in 5 M  guanidine and CFA. 
Because of the weak response from  these two groups of rabbits,  two more rabbits were in- 
jected with a mixture of ASF dissolved in 0.1 N sodium hydroxide and CFA. Initial immuniza- 
tion  consisted of  1-2  mg/rabbit  followed by  booster injections of 0.5-1  mg  at  weekly or 
biweekly intervals. Antisera from all three groups of rabbits were used in this study and be- 
haved identically. 
Double immunodiffusion was performed in 1% agar according to the method of Ouchterlony 
(8).  Immunoelectrophoresis was performed according to the method of Scheidegger (9). 
To test the specificity of the antisera, ~25I-labeled  DASF was precipitated by a "Sandwich" 
technique using rabbit anti-ASF and sheep antirabbit gamma globulin. 100 #i of rabbit anti- 
ASF or 100 #1 of rabbit antiperoxidase, as a control, were pipetted into each tube followed by 
10/~l of 125I-labeled DASF. The contents of the tubes were mixed and the tubes were incu- 
bated  for 2  h  at 37°C.  300 #l of sheep antirabbit  gamma globulin were pipetted into each 
tube, mixed, incubated at 37°C for 2 h, and then incubated overnight at 4°C. The tubes were 
then centrifuged for 20 min at 1,000 g and the supernatants removed. The precipitates were 
washed twice with 2  ml of cold saline and drained dry. The precipitates were then counted 
in a gamma counter (Nuclear-Chicago, Des Plaines, Ill.). 
Partial  Purification  of ASF  Related  Component .from Normal  Human  Serum.--Normal 
human serum was obtained from recently outdated blood from the Bellevue Hospital blood 
bank and concentrated five times by negative pressure dialysis. Starch zone electrophoresis 
was performed according  to  the  method  of Kunkel  (10).  Protein  determinations were per- 
formed using a  modified Folin  technique  (11).  Gel filtration was performed with Sephadex 
G-100 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) in 0.3 M  sodium chloride. 
RESULTS 
In order to prove that  the antiserum  was monospecific for ASF and not re- 
acting with  an unrelated  contaminant,  a  chemically pure preparation  of ASF 
from  a  patient  with  FMF  which had  given  a  single  band  on polyacrylamide 
electrophoresis and yielded an unambiguous amino acid sequence previously (1) 
was degraded, radioiodinated,  and reacted  with one of the antisera to ASK As 
shown in Table I, the antiserum  was able to precipitate over 75 %  of the TCA 
precipitable counts. 
TABLE  I 
Precipitation  of [  ~25I] DASF by Rabbit  Anti-ASF 
[~sI-]DASF  CPM precipitated  precipitated* 
10% TCA~  205,892  -- 
Rabbit anti-ASF§  157,948  76.7 
Control i!  3,346  I. 6 
Rabbit anti-ASV minus control  154,602  75.1 
* Percent cf CPM in TCA precipitate. 
,+ [12~I]DASI"  with 0.1  ml rabbit serum precipitated with 10c~  "['CA. 
§ [125I]DASF was incubated with rabbit anti-ASF and then with sheep antirabbit gamma- 
globulin. 
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Each of the  three  rabbit  antisera  to ASF gave a  single precipitin  line with 
DASF and also reacted with a component present in some human sera (Fig. 1). 
The  antisera  gave  lines  of  identity  with  DASF  from  patients  with  FMF, 
Hodgkin's disease, bronchiectasis,  and tuberculosis,  and they also gave lines of 
identity between these DASF's and the human serum component. On immuno- 
electrophoresis  the  DASF  moved as  a  single  band  towards  the  anode  in  the 
position of the #-globulin fraction of serum. 
To further  study  the  relation  of the  serum component to ASF,  absorption 
studies  were carried  out with  a  variety of sera and DASF. It was possible  to 
FIG. 1. Double immunodiffusion of anti-ASF vs. human serum and DASF demonstrating 
reactions  of identity.  1, anti-ASF;  F, DASF from a patient with  FMF; H, DASF from a 
patient  with  Hodgkin's  disease;  S,  serum  from  a  patient  with  tuberculosis  but  without 
amyloidosis. 
remove all  the activity of the antiserum by absorption with ASF, with positive 
human sera.  and even with an equal volume of normal sera that failed to give 
precipitin lines in agar. However, under similar conditions, five times the volume 
of pooled cord sera failed to remove the activity of the antiserum. 
Since  an  antigenically-related  component was noted in  certain  normal  and 
pathologic sera,  an attempt  was then  made to determine  the frequency of this 
component related to ASF in normal and pathologic sera. Using specific rabbit 
anti-ASF sera,  57 normal  sera and 89 sera from patients  with  diseases known 
to be frequently  associated with  amyloidosis, were tested  by double immuno- 
diffusion. As shown in Table II, the anti-ASF detected a circulating component 
in  only  7 %  of normal  sera  but  in  from 50-80%  of sera with  certain  chronic 
diseases.  Preliminary  studies  to  develop  an  immunoassay  to  quantitate  this 
component in  serum  have  proven difficult.  However,  using  the  immunoassay 
small amounts of reactive material have been detected in all of 11 normal sera 
tested. 3 This,  together with  the results  of the  absorption  studies  suggest  that 
this component may be present in small amounts in all normal sera. 
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TABLE II 
Frequency  of ASF Rdated Protein in Normal and Pathologic Sera* 
Diagnosis  No. tested  No. +  % 
Normal  57  4  7 
Primary and myeloma amyloid  17  9  53 
Secondary amyloid  8  7  88 
Myeloma  14  7  50 
Cirrhosis of the liver  11  6  55 
Tuberculosis  20  13  65 
Rheumatoid arthritis  10  7  70 
Hypo 7-globulinemla  9  6  67 
Pooled cord sera  4  0  0 
Isolated ]3 IP'.~  12  0  0 
* We would like to thank Doctors H. Kunkel, J. McClement, and D. Zimmon for contrib- 
uting some of the sera used in this study. 
In order to eliminate the possibility that the antisera might be detecting the 
P component, a protein that has been found adsorbed to the surface of amyloid 
fibrils  (12), purified P  component was  tested with  the  anti-ASF,  and DASF 
was reacted with anti-P component by double diffusion analysis.  4 As shown in 
Fig. 2, the anti-P component did not react with DASF, and the anti-ASF did 
not react with the P  component. 
An attempt was made to purify this circulating ASF component from normal 
human  serum.  On  immunoelectrophoresis  (Fig.  3),  the  reactive  component 
migrated more slowly than albumin.  Starch zone electrophoresis of five times 
concentrated human serum was then performed. The component was found to 
migrate to  the al-region as determined by double immunodiffusion analysis 
(Fig. 4). This portion of the starch block was eluted and the protein was con- 
centrated  by  negative  pressure  dialysis  and  subjected  to  chromatography 
on a Sephadex G-100 column in 0.3 M NaC1. As shown in Fig. 5, the circulating 
ASF component was found to elute just before albumin and therefore probably 
has a molecular weight slightly larger than albumin. Because of the very low 
yield, further purification has not been possible at this time. 
DISCUSSION 
The  present  study  presents  evidence  that  ASF,  the  major  nonimmuno- 
globulin related component of certain amyloids can be made to be immunogenic, 
and that an antiserum that was raised against a homogeneous and pure ASF 
protein from a  patient with  FMF  reacted identically with  DASF from four 
different patients. 
In attempting to understand  the possible origin of ASF it is important to 
4 We would like to thank Doctors Alan Cohen and Martha Skinner for generously supplying 
us with purified P component and anti-P component. M.  LEVIN~  M.  PRAS~ AND  E.  FRANKLIN  377 
FIG. 2. Double immunodiffusion of anti-ASF well no. 1, and anti-P component well no. 2 
vs. DASF, P component and human sera. F, DASF from a patient with FMF; M, serum from 
a patient with multiple myeloIna but without amyloidosis; N, normal human serum; P, puri- 
fied P component; X, normal saline. Both patterns are from the same plate. Fig. a was photo- 
graphed after 24 h of incubation while Fig. b was left to incubate for 48 h because the precipitin 
lines developed more slowly. Mter 48 h  the normal serum also had  a faint precipitin  line 
against anti-ASF. 
FIG. 3.  Immunoelectrophoresis of a  serum from a  patient with  secondary amyloidosis. 
The antigen well contains the serum, the upper trough contains horse antiwhole human serum, 
and the lower trough contains anti-ASF. The anode is on the right. 
note that  the  antiserum also  reacts with  a  component in human serum. Al- 
though the antiserum detects precipitin lines with only 7 % of normal sera, the 
other normal sera probably have the circulating component in lesser amounts 
since preliminary studies using a  radioimmunoassay appear to  detect  reactive 
material in all normal sera2 Pooled cord sera, however, seemingly did not have 
detectable amounts of reactive material as determined by the radio immuno- 
assay  3 and  failed  to  remove  the  activity of  the  antiserum under the  condi- 
tions of this study. These findings suggest that this component is not synthe- 
sized in utero and that the component does not cross the placenta. 
Precipitin tests, using this antiserum to ASF, detected an ASF related com- 
ponent in only 7 % of normal sera but detected elevated amounts of the circu- 
lating ASF component in from 50-80 % of patients with certain chronic diseases, 
some of which are often associated with amyloidosis. Furthermore, seven out of 
eight sera from patients with secondary amyloidosis and six of nine hypogamma- 
globulinemic sera gave precipitin lines with our antiserum. 378  NONIMMUNOGLOBULIN  AMYLOID-RELATED  COMPONENT  IN  SERIY~ 
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]710. 4. Starch zone electrophoresis of five times concentrated normal human serum. The + 
marks signify the tubes that gave precipitin  lines with anti-ASF.  The arrow  represents the 
sample origin, and the anode is on the right. 
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FIG.  5.  Gel  filtration  of the fraction containing the ASF  related  component obtained  by 
starch zone electrophoresis (Fig. 4). The ASF related component was chromatographed on a 
Sephadex G-100 column (190 X  3.5 cm) in 0.3 M  NaCI and 6 ml/tube was collected. Approxi- 
mately every  15 tubes were pooled, and the shaded area represents the two pools that gave 
precipitin lines with anti-ASF. The arrow  indicates the area where albumin eluted as deter- 
mined by immunodiffusion. M.  LEVIN,  M.  PRAS,  AND  E.  FRANKLIN  379 
While the serum component has not been fully characterized it is possible to 
describe some of its properties. It migrates in the od-globulin region  and ap- 
pears to be slightly larger than human albumin. It is not related to the P com- 
ponent,  another od-globulin known  to  be associated  with  amyloid deposits. 
While its precise nature remains unknown, this circulating ASF component may 
be either a substance that cross-reacts with ASF, a protein that binds ASF and 
reacts with  the antisera by virtue of its carrier properties, or a  precursor of 
ASF.  The possibility  that  the  antisera  are  directed  against  a  minor serum 
protein contaminant associated with  the ASF must  of course be considered. 
This seems unlikely in view of the fact that the antisera which precipitate more 
than 75 % of the DASF fraction which by other criteria was shown to be chemi- 
cally pure (1), give a reaction of identity between DASF and the al-globulin 
serum component. 
The finding of light chain fragments in primary and multiple myeloma as- 
sociated amyloidosis (5) and the in vitro synthesis of amyloid-like fibrils from 
light chains with enzyme digestion (13) suggests the possibility that ASF too, 
may be the result of proteolytic digestion of a circulating precursor which can 
assume the properties of amyloid fibrils. In this regard, it is interesting to note 
that the amino terminus of the ASF molecule is heterogeneous, possibly as a 
result of degradation.  Although  an ASF protein of 76 amino acids has been 
found in humans (1) and a similar protein containing 76 amino acids has been 
found in monkeys (2), a possible degradative origin is further supported by the 
finding of an ASF-like molecule containing only the first 45 amino acid residues 
in one patient (3) and a larger molecule with additional residues at the amino 
terminus in the duck.  5 This, plus the high incidence of positive reactions with 
sera from patients with  secondary amyloidosis and  certain chronic diseases, 
suggest that the circulating ASF component may be a  precursor of the ASF 
found in amyloid fibrils and that the ASF may be a proteolytic product. Further 
studies into the origin and biological functions of this circulating component may 
lead to an understanding of the pathogenesis of secondary and FMF associated 
amyloidosis. 
SUMMARY 
Antisera  have  been prepared  against  the  major nonimmunoglobulin com- 
ponent of secondary and familial Mediterranean fever (FMF) associated amy- 
loid which has been called A  component or acid soluble fraction (ASF). The 
antisera were shown to be monospecific for ASF by precipitation of 125I-labeled 
antigen and gave a reaction of identity with four different ASF preparations. 
The antisera were able to detect a circulating component in human serum that 
migrated in the al-globulin region. This circulating component gave a line of 
identity with degr,  aded ASF by double immunodiffusion. 57 normal sera and 89 
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sere from patients with diseases known to be frequently associated with amy- 
loidosis were  tested  by immunodiffusion for the  circulating ASF component. 
7 % of normal sere and 50-80 % of the pathologic sere had elevated amounts of 
this component. Absorption studies showed that all normal sera probably have 
small  amounts  of  this  component  while  cord  sera  do  not  have  detectable 
amounts.  This component was partially purified and was shown to be slightly 
Iarger  than  albumin.  The  relation  of  the  circulating  component  to  the  acid 
soluble fraction of amyloid is discussed. 
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